Filed with ASX · · 9 pages · English
The report highlights the completion of a capital raise to support the trial's commencement and the receipt of central ethics approval, which is crucial for patient enrollment. Additionally, the company reported a cash position increase and outlined its near-term outlook focused on finalizing site contracts and activating multiple trial sites across the USA.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Imagion Biosystems Limited ASX: IBX Imagion Biosystems Limited ASX: IBX ACN 616 305 027 Suite 2, Level 11 385 Bourke Street Melbourne VIC 3000 imagionbiosystems.com | investor@imagionbio.com A S X A N N O U N C E M E N T | 8 O c t o b e r 2 0 2 6 Quarterly Activities Report and Appendix 4C...
Imagion Biosystems Ltd. on 6ix
Follow Imagion Biosystems into a list and get an email when it puts out news.
Follow Imagion Biosystems